NEW YORK, March 14 - Oxford GlycoSciences and BioInvent International on Thursday said they are partnering for three years to identify, develop, manufacture, and commercialize therapeutic antibodies.
 
Terms of the agreement call for OGS to provide at least five target antigens per year, which it will identify and validate through its proteomics process. BioInvent, in turn, will apply its n-CoDeR phage display library to identify antibodies targeted to those antigens.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.